Public Procurement of Medicines: A Taxonomy of Procurement Systems in Europe

Maximilian Salcher-Konrad, Katharina Habimana, Sabine Vogler

WHO Collaborating Centre for Pharmaceutical Pricing and Reimbursement Policies, Pharmacoeconomics Department, Gesundheit Österreich (Austrian National Public Health Institute/GÖG), Vienna, Austria

HPR199 ISPOR Europe 2022


What did we do?

- Public procurement of medicines (e.g. through tendering) attracts attention by policy-makers seeking to achieve better patient access to affordable medicines. However, it is unclear how public procurement procedures are organised in European countries and how these systems perform.
- We mapped public procurement practices for medicines in 32 European countries (all European Union member states, Iceland, Liechtenstein, Norway, Switzerland, United Kingdom) using the following sources:
 - Targeted literature searches
 - Expert interviews
 - Tenders European Daily (TED) database


What did we find?

We identified **four core organisational forms** for public procurement of medicines in Europe (see figures). Countries often apply several of these forms simultaneously and to various extent, e.g. one form for all medicines used in hospitals, and another form only for vaccines used in national immunisation programmes.


Facility-based procurement




Regional centralised procurement



Group (joint) procurement



National centralised procurement



In addition to procurement within countries, European countries engage in cross-country joint procurement, including for COVID-19 vaccines and therapeutics (all EU member states), and in some cases for other vaccines (Baltic Procurement Initiative) and hospital medicines (joint Nordic tenders).

Legend:

- Applied in outpatient and inpatient sectors
 - Not applied
- Applied only in inpatient sector
- Applied only in outpatient sector
- No information / Country not included in study

What does this mean?

- Countries typically apply a mix of organisational forms for procurement of medicines. While joint procurement within countries and across countries may hold some advantages, such as greater purchasing power and increasing the attractiveness of the market for suppliers, European countries continue to procure large volumes of medicines at sub-national and, in many cases, at facility-level.
- There is scope for optimising public procurement of medicines in Europe through strategic use of different organisational forms of procurement.

Gesundheit Österreich GmbH, Stubenring 6, 1010 Vienna, Austria. www.goeg.at & ppri.goeg.at



The study was commissioned in the frame of the SC 2020 7304 under the FWC SANTE/2016/A1/039 – Lot 1 by the European Health and Digital Executive Agency (HaDEA). The information and views set out in this poster are those of the authors and do not necessarily reflect the official opinion of the Commission/Executive Agency. Neither the Commission/Executive Agency nor any person acting on the Commission's/Executive Agency's behalf may be held responsible for the use which may be made of the information contained therein.

